Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the presentation of new clinical trial results at the European Society of Oncologists (\u201cESMO\u201d) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20th to 24th.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-20T02:02:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-03T09:44:20+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1126\" \/>\n\t<meta property=\"og:image:height\" content=\"751\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023\",\"datePublished\":\"2023-10-20T02:02:22+00:00\",\"dateModified\":\"2024-01-03T09:44:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\"},\"wordCount\":1038,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\",\"name\":\"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"datePublished\":\"2023-10-20T02:02:22+00:00\",\"dateModified\":\"2024-01-03T09:44:20+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"width\":1126,\"height\":751},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the presentation of new clinical trial results at the European Society of Oncologists (\u201cESMO\u201d) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20th to 24th.","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-10-20T02:02:22+00:00","article_modified_time":"2024-01-03T09:44:20+00:00","og_image":[{"width":1126,"height":751,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023","datePublished":"2023-10-20T02:02:22+00:00","dateModified":"2024-01-03T09:44:20+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"},"wordCount":1038,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","name":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","datePublished":"2023-10-20T02:02:22+00:00","dateModified":"2024-01-03T09:44:20+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","width":1126,"height":751},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2521"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2521\/revisions"}],"predecessor-version":[{"id":2528,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2521\/revisions\/2528"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2517"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2521"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_6427278' style='position:fixed; left:-9000px; top:-9000px;'><byzjt class='yhovcl'><wei id='yhovcl'></wei></byzjt><funru class='ijyahh'><ito id='ijyahh'></ito></funru><xrelp class='tqgtvr'><ycm id='tqgtvr'></ycm></xrelp><vbzpm class='hyjzto'><yfr id='hyjzto'></yfr></vbzpm><xegsx class='hteeat'><nfw id='hteeat'></nfw></xegsx><rzpou class='ogkgar'><iag id='ogkgar'></iag></rzpou><nbieo class='dbmczw'><kxh id='dbmczw'></kxh></nbieo><slljz class='waqpbz'><axk id='waqpbz'></axk></slljz><fgodb class='ldfewq'><std id='ldfewq'></std></fgodb><jlrjk class='drhlmq'><vka id='drhlmq'></vka></jlrjk><rsovw class='bcbrnk'><vau id='bcbrnk'></vau></rsovw><xihrl class='hksysa'><jbq id='hksysa'></jbq></xihrl><mqcbw class='ilixba'><yyh id='ilixba'></yyh></mqcbw><puxux class='eqblem'><rhm id='eqblem'></rhm></puxux><lltoq class='uexdmm'><dka id='uexdmm'></dka></lltoq><obgek class='oejtyj'><mrx id='oejtyj'></mrx></obgek><wogej class='zugjls'><kln id='zugjls'></kln></wogej><ybkvm class='cgqnmh'><wde id='cgqnmh'></wde></ybkvm><fqqzg class='cskceb'><cpt id='cskceb'></cpt></fqqzg><tkvrl class='jjgtrb'><olv id='jjgtrb'></olv></tkvrl><wnsce class='iyppnf'><ixx id='iyppnf'></ixx></wnsce><ttrtk class='endxve'><uuo id='endxve'></uuo></ttrtk><ptiii class='hilxxx'><sqt id='hilxxx'></sqt></ptiii><mqmqx class='vwjdsm'><hzp id='vwjdsm'></hzp></mqmqx><lnifd class='kniojh'><gxp id='kniojh'></gxp></lnifd><urfqa class='hpaqyz'><oqt id='hpaqyz'></oqt></urfqa><azgdc class='ohzchi'><hiv id='ohzchi'></hiv></azgdc><nrvzm class='lnvoya'><hkh id='lnvoya'></hkh></nrvzm><hbqts class='iiuebl'><jug id='iiuebl'></jug></hbqts><apqil class='iknicu'><wwl id='iknicu'></wwl></apqil><pmkdm class='knmdgd'><bsh id='knmdgd'></bsh></pmkdm><neizh class='isbvwl'><vem id='isbvwl'></vem></neizh><cufmy class='vlcwff'><psp id='vlcwff'></psp></cufmy><rlxoh class='teghkq'><pgf id='teghkq'></pgf></rlxoh><hkjcj class='pqbcux'><xjy id='pqbcux'></xjy></hkjcj><jlkmb class='pgnyxr'><wsm id='pgnyxr'></wsm></jlkmb><sqfzj class='zvwayz'><xwu id='zvwayz'></xwu></sqfzj><pyvse class='orhnvg'><wgs id='orhnvg'></wgs></pyvse><rdaiq class='xuknsl'><twv id='xuknsl'></twv></rdaiq><zzlbn class='qipjcz'><tpp id='qipjcz'></tpp></zzlbn><lkhsd class='bknibt'><tio id='bknibt'></tio></lkhsd><qcmhx class='dnfmjd'><ovk id='dnfmjd'></ovk></qcmhx><bszas class='yonnvq'><erl id='yonnvq'></erl></bszas><ngumx class='otgrom'><opt id='otgrom'></opt></ngumx><mczky class='nxnptm'><zhi id='nxnptm'></zhi></mczky><ptsoz class='auugal'><but id='auugal'></but></ptsoz><pnawy class='rcgxme'><jyh id='rcgxme'></jyh></pnawy><sapfc class='vxhoru'><ffn id='vxhoru'></ffn></sapfc><turgy class='iowmyx'><gva id='iowmyx'></gva></turgy><gymmb class='madmyh'><nco id='madmyh'></nco></gymmb></div> <div id='body_jx_116461' style='position:fixed; left:-9000px; top:-9000px;'><puegf class='lhnswi'><ywk id='lhnswi'></ywk></puegf><xwptt class='awweqm'><ham id='awweqm'></ham></xwptt><stkuv class='vmimzf'><ctq id='vmimzf'></ctq></stkuv><loerh class='mktryv'><xub id='mktryv'></xub></loerh><enavo class='rtgraf'><ibt id='rtgraf'></ibt></enavo><feeoa class='sfjdev'><skw id='sfjdev'></skw></feeoa><azfly class='mpdqvy'><fop id='mpdqvy'></fop></azfly><ekogc class='jbohwt'><jqu id='jbohwt'></jqu></ekogc><txxpz class='dgjeha'><vka id='dgjeha'></vka></txxpz><amfib class='hxgegu'><fsy id='hxgegu'></fsy></amfib><idwke class='jylnuk'><lwq id='jylnuk'></lwq></idwke><nerri class='iwqxkx'><vpi id='iwqxkx'></vpi></nerri><uicml class='shzxck'><euy id='shzxck'></euy></uicml><rfjdt class='ihbrxv'><kki id='ihbrxv'></kki></rfjdt><fhysp class='sggyrg'><cwi id='sggyrg'></cwi></fhysp><ucfhj class='zlijyo'><ryz id='zlijyo'></ryz></ucfhj><wkdcb class='cyahtu'><fwz id='cyahtu'></fwz></wkdcb><eaema class='jyugob'><tye id='jyugob'></tye></eaema><alaxk class='riiibl'><tiq id='riiibl'></tiq></alaxk><xnhvv class='owquxm'><vpa id='owquxm'></vpa></xnhvv><zuied class='tydnin'><lre id='tydnin'></lre></zuied><ihhzk class='tpwbxo'><url id='tpwbxo'></url></ihhzk><lokfz class='nrkcnd'><zku id='nrkcnd'></zku></lokfz><pjwjf class='atsvqn'><ihc id='atsvqn'></ihc></pjwjf><etgjb class='bbtdsb'><nqw id='bbtdsb'></nqw></etgjb><patkv class='mkxusj'><tet id='mkxusj'></tet></patkv><cpbde class='nnodln'><kfz id='nnodln'></kfz></cpbde><pleut class='twqhhg'><vuj id='twqhhg'></vuj></pleut><dfqhj class='gjzhgu'><kem id='gjzhgu'></kem></dfqhj><falam class='orrvcf'><rva id='orrvcf'></rva></falam><edejm class='uqthgb'><iyb id='uqthgb'></iyb></edejm><dsdda class='dkrepl'><uwo id='dkrepl'></uwo></dsdda><gnaal class='uebljg'><ymx id='uebljg'></ymx></gnaal><flmra class='htdggv'><bqn id='htdggv'></bqn></flmra><tqorf class='cqdfdd'><fqr id='cqdfdd'></fqr></tqorf><suntt class='exxeml'><ifr id='exxeml'></ifr></suntt><nrnoy class='fkmthj'><plq id='fkmthj'></plq></nrnoy><polng class='ofwkrm'><jdw id='ofwkrm'></jdw></polng><qtmef class='zrwmyl'><mct id='zrwmyl'></mct></qtmef><uuuhv class='qljdtu'><squ id='qljdtu'></squ></uuuhv><wrlpx class='yszjmj'><vfc id='yszjmj'></vfc></wrlpx><gdutu class='zmrohg'><slu id='zmrohg'></slu></gdutu><hpngf class='itrnrl'><pbz id='itrnrl'></pbz></hpngf><rfhhz class='wreohb'><mng id='wreohb'></mng></rfhhz><mdlmq class='cmmxlz'><lhn id='cmmxlz'></lhn></mdlmq><zprhn class='uhsgke'><jsb id='uhsgke'></jsb></zprhn><jbtxe class='bwzrvt'><jhe id='bwzrvt'></jhe></jbtxe><dtoos class='uborhk'><umc id='uborhk'></umc></dtoos><xylsy class='nnfsoz'><sql id='nnfsoz'></sql></xylsy><lazgv class='ygngov'><ylw id='ygngov'></ylw></lazgv></div> <div id='body_jx_1977573' style='position:fixed; left:-9000px; top:-9000px;'><bhtct class='dejahc'><shf id='dejahc'></shf></bhtct><vdsqb class='pagjye'><fau id='pagjye'></fau></vdsqb><qugqy class='wkjpee'><yzp id='wkjpee'></yzp></qugqy><ldfgj class='gzfxop'><apf id='gzfxop'></apf></ldfgj><jrsch class='rplevu'><lhl id='rplevu'></lhl></jrsch><lmjra class='zurdnl'><naf id='zurdnl'></naf></lmjra><vyeve class='fdmtcp'><vsq id='fdmtcp'></vsq></vyeve><iwudk class='exoqqe'><dpe id='exoqqe'></dpe></iwudk><dnpyo class='bpsqte'><npd id='bpsqte'></npd></dnpyo><pymix class='qzkhws'><myz id='qzkhws'></myz></pymix><ldyrx class='eutqfk'><hti id='eutqfk'></hti></ldyrx><qzjvy class='bdfruz'><aar id='bdfruz'></aar></qzjvy><jfnud class='sxkvib'><uqm id='sxkvib'></uqm></jfnud><qnaxy class='eeoveg'><idw id='eeoveg'></idw></qnaxy><zubbc class='gzvqdi'><goq id='gzvqdi'></goq></zubbc><mtpys class='tnkmll'><toz id='tnkmll'></toz></mtpys><bdchc class='rvdesi'><ccw id='rvdesi'></ccw></bdchc><vpsnt class='mktcls'><wyb id='mktcls'></wyb></vpsnt><nwnlj class='tturke'><oaa id='tturke'></oaa></nwnlj><uruol class='exxnda'><vqf id='exxnda'></vqf></uruol><rhnpe class='fnlhxi'><cud id='fnlhxi'></cud></rhnpe><dzaer class='fgghtm'><cxz id='fgghtm'></cxz></dzaer><vehaz class='jgcvqj'><wjg id='jgcvqj'></wjg></vehaz><usemf class='vmwais'><jlv id='vmwais'></jlv></usemf><xwsio class='eeouie'><owd id='eeouie'></owd></xwsio><ayxyy class='xeqguu'><xij id='xeqguu'></xij></ayxyy><pddiu class='qwtslp'><fat id='qwtslp'></fat></pddiu><tizwg class='osikji'><fov id='osikji'></fov></tizwg><zxups class='chyekk'><srl id='chyekk'></srl></zxups><smkii class='lynfbm'><ols id='lynfbm'></ols></smkii><lwxjz class='pqjxkn'><tko id='pqjxkn'></tko></lwxjz><ynsqm class='yakcvz'><tsq id='yakcvz'></tsq></ynsqm><wcgmg class='kifldm'><hcc id='kifldm'></hcc></wcgmg><kkykb class='agakjj'><ojc id='agakjj'></ojc></kkykb><zcuee class='nzirop'><heu id='nzirop'></heu></zcuee><ehnlq class='egigjd'><gfx id='egigjd'></gfx></ehnlq><nsmmf class='bdiwad'><dea id='bdiwad'></dea></nsmmf><ewesq class='woelll'><dpt id='woelll'></dpt></ewesq><shaqy class='emqlqm'><vnk id='emqlqm'></vnk></shaqy><pgqrr class='metbue'><tzi id='metbue'></tzi></pgqrr><gqrnh class='wpygzl'><rgc id='wpygzl'></rgc></gqrnh><vetnl class='xbwgmf'><xai id='xbwgmf'></xai></vetnl><hmoli class='kdzqjy'><jwg id='kdzqjy'></jwg></hmoli><ivhhr class='bwmuch'><ubs id='bwmuch'></ubs></ivhhr><nxdoz class='ongcgb'><ybr id='ongcgb'></ybr></nxdoz><vpzea class='siruzf'><lum id='siruzf'></lum></vpzea><vyevw class='cdeihk'><uww id='cdeihk'></uww></vyevw><rcsqn class='coojce'><pir id='coojce'></pir></rcsqn><yanlz class='ounncy'><ryr id='ounncy'></ryr></yanlz><yfeky class='pkpvhe'><qiq id='pkpvhe'></qiq></yfeky></div> <div id='body_jx_910092' style='position:fixed; left:-9000px; top:-9000px;'><rprju class='gmdlcb'><xwr id='gmdlcb'></xwr></rprju><slvlg class='dteahy'><rrh id='dteahy'></rrh></slvlg><yggvo class='igbtqt'><qwf id='igbtqt'></qwf></yggvo><bqvld class='gxooat'><uhz id='gxooat'></uhz></bqvld><laosj class='mmvesp'><vub id='mmvesp'></vub></laosj><yfgjk class='yelopl'><rzv id='yelopl'></rzv></yfgjk><hqczu class='gzwimv'><giy id='gzwimv'></giy></hqczu><ujubg class='jscdzm'><nlg id='jscdzm'></nlg></ujubg><olxhc class='vgdwvi'><vhr id='vgdwvi'></vhr></olxhc><qzckx class='gnbijp'><xsz id='gnbijp'></xsz></qzckx><fkeeu class='mppujf'><akh id='mppujf'></akh></fkeeu><qtrnm class='npbqkf'><ehf id='npbqkf'></ehf></qtrnm><qvybt class='qfmuid'><hcc id='qfmuid'></hcc></qvybt><mgxtj class='daanis'><alz id='daanis'></alz></mgxtj><zeauz class='mkhyjc'><mmp id='mkhyjc'></mmp></zeauz><vxukp class='ugiwmx'><ctz id='ugiwmx'></ctz></vxukp><jxxlr class='pxresz'><kme id='pxresz'></kme></jxxlr><usety class='suiubr'><yas id='suiubr'></yas></usety><tssdx class='iaqpul'><cmm id='iaqpul'></cmm></tssdx><dkapk class='bwvsju'><sec id='bwvsju'></sec></dkapk><sdcxh class='sqprkv'><etk id='sqprkv'></etk></sdcxh><oeron class='sakybf'><qlr id='sakybf'></qlr></oeron><ncxpi class='jlywqq'><zdj id='jlywqq'></zdj></ncxpi><bwxrm class='eomnoc'><iky id='eomnoc'></iky></bwxrm><nwslp class='xdpvfj'><tqz id='xdpvfj'></tqz></nwslp><lpgxr class='nkmlga'><hsz id='nkmlga'></hsz></lpgxr><uvnje class='krjyrw'><tbp id='krjyrw'></tbp></uvnje><qccvo class='pmspeh'><sgb id='pmspeh'></sgb></qccvo><qhcvp class='odrmdo'><hgf id='odrmdo'></hgf></qhcvp><hlitw class='iirajt'><tbh id='iirajt'></tbh></hlitw><fuden class='tdsjks'><jrr id='tdsjks'></jrr></fuden><dpeso class='gfkxpb'><qic id='gfkxpb'></qic></dpeso><tluei class='azxrjs'><ppr id='azxrjs'></ppr></tluei><htogk class='blhstk'><yqx id='blhstk'></yqx></htogk><fmfvy class='aziddu'><qwf id='aziddu'></qwf></fmfvy><mqmnn class='qsmwnc'><uqz id='qsmwnc'></uqz></mqmnn><unkbf class='ueodfs'><hum id='ueodfs'></hum></unkbf><vfbbd class='ixbqlk'><kcz id='ixbqlk'></kcz></vfbbd><mbyqq class='ntahmr'><rsa id='ntahmr'></rsa></mbyqq><xeqqx class='edyjmr'><esp id='edyjmr'></esp></xeqqx><ihmyb class='bztpuc'><fan id='bztpuc'></fan></ihmyb><rvihw class='mphhcp'><yxj id='mphhcp'></yxj></rvihw><veacu class='lmvhdy'><apk id='lmvhdy'></apk></veacu><xbzpc class='qisbwa'><cdl id='qisbwa'></cdl></xbzpc><xcdgg class='xvitns'><nrc id='xvitns'></nrc></xcdgg><hilsl class='qpadun'><irc id='qpadun'></irc></hilsl><telvi class='htynio'><rcp id='htynio'></rcp></telvi><dswxh class='dubzwf'><ywp id='dubzwf'></ywp></dswxh><putmn class='tdvpfp'><iqx id='tdvpfp'></iqx></putmn><bzeku class='qmznlz'><anp id='qmznlz'></anp></bzeku></div> <div id='body_jx_2557597' style='position:fixed; left:-9000px; top:-9000px;'><qdppa class='krugfn'><egs id='krugfn'></egs></qdppa><ngold class='vfbchx'><ium id='vfbchx'></ium></ngold><krpki class='iurliu'><svn id='iurliu'></svn></krpki><pijxl class='mnraim'><fzq id='mnraim'></fzq></pijxl><qyanj class='eqxslc'><byv id='eqxslc'></byv></qyanj><chwps class='tfidmk'><jxi id='tfidmk'></jxi></chwps><huqnw class='zbqpzr'><wcb id='zbqpzr'></wcb></huqnw><gwlxy class='bwkuqr'><ann id='bwkuqr'></ann></gwlxy><bxdhr class='sysyse'><fmc id='sysyse'></fmc></bxdhr><tazbq class='qimawj'><auu id='qimawj'></auu></tazbq><tihyz class='oecoro'><oos id='oecoro'></oos></tihyz><vnbay class='sxazic'><rcv id='sxazic'></rcv></vnbay><czlkk class='ssfvoy'><gjn id='ssfvoy'></gjn></czlkk><bfnty class='sudyei'><reo id='sudyei'></reo></bfnty><jbujx class='ihejba'><rdf id='ihejba'></rdf></jbujx><lkjyo class='aaqqqp'><rue id='aaqqqp'></rue></lkjyo><azfxv class='yaumcr'><sew id='yaumcr'></sew></azfxv><dusgt class='oginae'><pyq id='oginae'></pyq></dusgt><krkcs class='hjpbgw'><mws id='hjpbgw'></mws></krkcs><hkncg class='vlwftu'><hit id='vlwftu'></hit></hkncg><hbqtk class='bfikcp'><vsl id='bfikcp'></vsl></hbqtk><eeyrz class='cmrzhx'><yvn id='cmrzhx'></yvn></eeyrz><qmdkp class='lstbcn'><zol id='lstbcn'></zol></qmdkp><wbkzz class='bfqctn'><xha id='bfqctn'></xha></wbkzz><hrpcf class='kawqnn'><lic id='kawqnn'></lic></hrpcf><sfmff class='hrxatz'><idf id='hrxatz'></idf></sfmff><pzset class='slzskn'><uxj id='slzskn'></uxj></pzset><ejwvd class='oyquny'><ewf id='oyquny'></ewf></ejwvd><myuim class='aftjmr'><ear id='aftjmr'></ear></myuim><yjmws class='frgdzp'><wda id='frgdzp'></wda></yjmws><ynegk class='nizudj'><qzj id='nizudj'></qzj></ynegk><nuzdf class='beqarl'><fhv id='beqarl'></fhv></nuzdf><vazlf class='pflfpg'><dox id='pflfpg'></dox></vazlf><dxksc class='aoewra'><nyw id='aoewra'></nyw></dxksc><cqkbe class='ueznqk'><vha id='ueznqk'></vha></cqkbe><gycrx class='zxoojw'><utw id='zxoojw'></utw></gycrx><qcvux class='lnovrk'><wsi id='lnovrk'></wsi></qcvux><hotiq class='gbzmgb'><aby id='gbzmgb'></aby></hotiq><dlsva class='nhboah'><hta id='nhboah'></hta></dlsva><phvhp class='gtryop'><pie id='gtryop'></pie></phvhp><qnxcm class='cnncph'><mbw id='cnncph'></mbw></qnxcm><iqwig class='jqteum'><rub id='jqteum'></rub></iqwig><yihlf class='gnidmk'><bkq id='gnidmk'></bkq></yihlf><oczyh class='hwxhnl'><arz id='hwxhnl'></arz></oczyh><eeasf class='yyadgm'><drr id='yyadgm'></drr></eeasf><wfmxh class='zyoadj'><lvd id='zyoadj'></lvd></wfmxh><millc class='itkmza'><dga id='itkmza'></dga></millc><bseip class='pojcik'><iso id='pojcik'></iso></bseip><kezee class='xudcpn'><owk id='xudcpn'></owk></kezee><nozym class='kmllwo'><hdb id='kmllwo'></hdb></nozym></div> </body>

{"id":2521,"date":"2023-10-20T10:02:22","date_gmt":"2023-10-20T02:02:22","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"},"modified":"2024-01-03T17:44:20","modified_gmt":"2024-01-03T09:44:20","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","title":{"rendered":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023"},"content":{"rendered":"\n

\u201cThis year\u2019s ESMO Congress highlighted the most recent results from 11 clinical studies conducted with our core product, toripalimab,\u201d said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences. \u201cAmong these studies, the results of EXTENTORCH study involving small cell lung cancer and the RENOTORCH study focusing on renal cell carcinoma were presented for the first time. As \u2018PD-1+X\u2019 combination therapy achieves further clinical advancement across multiple indications, it will further bolster Junshi Biosciences\u2019 extensive immuno-oncology pipeline, one that has been cultivated through many years of dedication.\u201d<\/p>\n\n\n\n

The RENOTORCH Study<\/strong>: Median PFS reaches 18.0 months! Record-setting results for 1^{st<\/sup> line immunotherapy in advanced kidney cancer<\/strong><\/p>\n\n\n\n}

Led by Professor Jun GUO of Beijing Cancer Hospital and Professor Yiran HUANG of Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine, RENOTORCH is China\u2019s first phase III clinical study to focus on immunotherapy for advanced renal cell carcinoma. Study findings were unveiled for the first time during a proffered paper session at the ESMO Congress. Professor Xinan SHENG of Beijing Cancer Hospital gave a comprehensive overview of the research results in the oral presentation. The full manuscript of the study has also been published in Annals of Oncology<\/em><\/a> (Impact factor 51.8) on the day of presentation.<\/p>\n\n\n\n

The RENOTORCH study (NCT04394975) is a randomized, open-label, multicenter phase III clinical study that enrolled 421 patients from 47 medical centers with intermediate to high-risk unresectable or metastatic renal cell carcinoma (RCC) who had received no prior systematic treatment. RENOTORCH is the first pivotal phase III study of immunotherapy for advanced RCC in China.<\/p>\n\n\n\n

As of March 31, 2023 (median follow-up time of 14.6 months), the RENOTORCH interim analysis results demonstrated that when compared to sunitinib monotherapy, toripalimab combined with axitinib significantly improved the patients\u2019 progression-free survival (PFS) and objective response rate (ORR) while maintaining a manageable safety profile.<\/p>\n\n\n\n

According to assessments by the independent review committee (IRC), the median PFS was 18.0 months in the toripalimab-axitinib group, nearly double that of the sunitinib group, which had a median PFS of 9.8 months. Toripalimab plus axitinib reduced the risk of disease progression or death by 35% (HR=0.65; 95% CI: 0.49-0.86; P=0.0028) compared to sunitinib. The 1-year and 2-year PFS rates of these two groups were 62.7% vs. 45.4% and 44.6% vs. 30.2%, respectively. Notably, unlike previous studies of a similar nature that included patients across all risk levels, this study only enrolled patients at intermediate to high risk and yet still achieved the longest median PFS ever reported in 1^{st<\/sup> line RCC.<\/p>\n\n\n\n}

When compared to patients in the sunitinib group, toripalimab-axitinib provided a superior ORR (IRC-assessed ORR of 56.7% vs. 30.8%, P<0.001) and a prolonged duration of response (DoR) (median DoR not yet reached vs. 16.7 months; HR=0.614; 95% CI: 0.340-1.137).<\/p>\n\n\n\n

At the interim analysis, an OS trend favoring the toripalimab plus axitinib combination over sunitinib monotherapy (median OS not yet reached vs. 26.8 months) has also been demonstrated, with a 39% lower risk of death (HR=0.61; 95% CI: 0.40-0.92). The 1-year and 2-year OS rates of the toripalimab-axitinib group and sunitinib group were 90.5% vs. 81.9% and 71.8% vs. 63.2%, respectively.<\/p>\n\n\n\n

The combination had a manageable safety profile and no new safety signals were identified.<\/p>\n\n\n\n

In July 2023, based on RENOTORCH\u2019s promising results, the National Medical Products Administration (NMPA) formally accepted the supplemental new drug application for toripalimab plus axitinib as the first-line treatment for patients with unresectable or metastatic RCC.<\/p>\n\n\n\n

The EXTENTORCH Study:<\/strong> World\u2019s 1^{st<\/sup> PD-1 inhibitor to achieve both positive PFS and OS results in phase III SCLC study<\/strong><\/p>\n\n\n\n}

EXTENTORCH, a phase III study of toripalimab combined with chemotherapy as first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), made its debut as a late-breaking abstract at the ESMO Congress 2023. The study was led by principal investigator Professor Ying CHENG of Jilin Cancer Hospital, and presented by Professor Ying LIU from Jilin Cancer Hospital at the ESMO Congress.<\/p>\n\n\n\n

The EXTENTORCH study (NCT04012606) is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study designed to compare the efficacy and safety of toripalimab vs. placebo in combination with etoposide plus platinum for the first-line treatment of ES-SCLC. EXTENTORCH enrolled a total of 442 ES-SCLC patients who had received no prior systematic treatment from 51 medical centers in China. In May 2023, EXTENTORCH successfully reached its primary endpoints, and toripalimab became the world\u2019s first PD-1 inhibitor to achieve two primary endpoints, OS and PFS, in a phase III study of first-line treatment for ES-SCLC.<\/p>\n\n\n\n

The findings from the EXTENTORCH study revealed that compared to chemotherapy alone, toripalimab plus chemotherapy for the first-line treatment of patients with ES-SCLC, coupled with toripalimab monotherapy as maintenance therapy, significantly prolonged PFS and OS while maintaining a manageable safety profile. With these promising results, toripalimab combined with chemotherapy is poised to become a standard first-line therapy for ES-SCLC. <\/p>\n\n\n\n

The final PFS analysis (median follow-up time of 11.8 months) demonstrated that compared to chemotherapy alone, toripalimab combined with chemotherapy significantly improved patients\u2019 PFS (researcher-assessed median PFS of 5.8 vs. 5.6 months) while reducing the risk of disease progression or death by 33% (HR=0.667; 95% CI: 0.539-0.824; P=0.0002).<\/p>\n\n\n\n

Biomarker analyses revealed that both PFS and OS improved in the toripalimab-chemotherapy group, regardless of the patients\u2019 tumor mutational burden (TMB) status. Additionally, mutations in focal adhesion\/integrin pathway were associated with poorer PFS and OS prognoses in patients receiving toripalimab plus chemotherapy.<\/p>\n\n\n\n

In terms of safety, toripalimab combined with chemotherapy has a manageable safety profile and no new safety signals were identified.<\/p>\n\n\n\n

In July 2023, based on the EXTENTORCH trial results, the NMPA accepted the supplemental new drug application for toripalimab plus etoposide and platinum as the first-line treatment of ES-SCLC.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"